Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 106Cyclophosphamide 97Cisplatin 75Carboplatin 66Fluorouracil 64Etoposide 61Doxorubicin 60Chemotherapy, Adjuvant 60Vincristine 56Peripheral Blood Stem Cell Transplantation 48Filgrastim 47Paclitaxel 46Gemcitabine 44Cytarabine 41Neoadjuvant Therapy 40Leucovorin 40Docetaxel 35Melphalan 31Oxaliplatin 29Methotrexate 29Ifosfamide 25Gene Expression Profiling 25Amplified Fragment Length Polymorphism Analysis 24Immunohistochemistry 23Dexamethasone 22Irinotecan 21aldesleukin 20Prednisolone 20Interferon-alpha 20Tamoxifen 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × NIH × lometrexol × Clear all
NCT00033722 2014-01-06

Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00024310 2013-09-17

Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1 Unknown

Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡